Late HCC onset after DAAs therapy in patients with SVR: a type D ADR that requires a longer follow-up?
作者信息
Nappi Antonella, Perrella Alessandro, Rinaldi Luca, Izzi Antonio, Punzi Rodolfo, Adinolfi Luigi Elio, Sbeglia Costanza, Bellopede Pasquale, Maddaloni Adelaide, Papa Nunzia, Spatarella Micaela
机构信息
HospitalPharmacy - Pharmacovigilance Unit, Ospedali dei Colli, P.O. D.Cotugno, Naples, Italy.
VII Unit InfectiousDiseaseand Immunology, Ospedali dei Colli P.O. D.Cotugno, Naples, Italy.
出版信息
Eur J Hosp Pharm. 2019 Jul;26(4):243-244. doi: 10.1136/ejhpharm-2019-001975. Epub 2019 Jun 14.
Abstract
摘要
相似文献
1
Late HCC onset after DAAs therapy in patients with SVR: a type D ADR that requires a longer follow-up?在实现持续病毒学应答（SVR）的患者中，直接抗病毒药物（DAA）治疗后晚期肝细胞癌（HCC）的发生：一种需要更长随访时间的D型药物不良反应（ADR）？
Eur J Hosp Pharm. 2019 Jul;26(4):243-244. doi: 10.1136/ejhpharm-2019-001975. Epub 2019 Jun 14.
2
Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.直接作用抗病毒药物治疗的丙型肝炎相关肝硬化患者肝细胞癌的发生率。
Gastroenterology. 2018 Aug;155(2):411-421.e4. doi: 10.1053/j.gastro.2018.04.008. Epub 2018 Apr 12.
3
Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.直接作用抗病毒药物的持续病毒学应答可预测丙型肝炎病毒感染患者的更好结局：一项回顾性研究。
World J Gastroenterol. 2019 Oct 28;25(40):6094-6106. doi: 10.3748/wjg.v25.i40.6094.
4
Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.在纳入监测项目的肝硬化患者中，直接抗病毒治疗 HCV 后肝细胞癌的发生率。
Gastroenterology. 2018 Nov;155(5):1436-1450.e6. doi: 10.1053/j.gastro.2018.07.015. Epub 2018 Jul 19.
5
Management of HCV-related decompensated cirrhosis with direct-acting antiviral agents: who should be treated?直接作用抗病毒药物治疗丙型肝炎相关失代偿期肝硬化：哪些患者应接受治疗？
Hepatol Int. 2019 Mar;13(2):165-172. doi: 10.1007/s12072-019-09933-8. Epub 2019 Feb 13.
6
Clinical characteristics and prognosis of HCC occurrence after antiviral therapy for HCV patients between sustained and non-sustained responders.慢性丙型肝炎病毒感染者经抗病毒治疗后持续应答与无持续应答者发生肝细胞癌的临床特征和预后
J Formos Med Assoc. 2019 Jan;118(1 Pt 3):504-513. doi: 10.1016/j.jfma.2018.10.017. Epub 2018 Dec 4.
7
Hepatocellular Carcinoma after Achievement of Sustained Viral Response with Daclatasvir and Asunaprevir in Patients with Chronic Hepatitis C Virus Infection.慢性丙型肝炎病毒感染患者使用达卡他韦和阿舒瑞韦实现持续病毒学应答后发生肝细胞癌
Dig Dis. 2017;35(6):565-573. doi: 10.1159/000480183. Epub 2017 Oct 17.
8
Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals.直接作用抗病毒药物治疗的丙型肝炎肝硬化患者发生肝细胞癌的预测因素。
Dig Liver Dis. 2019 Feb;51(2):310-317. doi: 10.1016/j.dld.2018.10.014. Epub 2018 Oct 31.
9
Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents.直接作用抗病毒药物治疗的 HCV 患者的肝细胞癌风险。
Gastroenterology. 2017 Oct;153(4):996-1005.e1. doi: 10.1053/j.gastro.2017.06.012. Epub 2017 Jun 19.
10
Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.肝细胞癌会降低使用直接作用抗病毒药物成功治疗丙型肝炎病毒的几率。
J Hepatol. 2017 Jun;66(6):1173-1181. doi: 10.1016/j.jhep.2017.01.020. Epub 2017 Feb 2.
引用本文的文献
1
Hypernatremia During Intravenous Treatment With Fosfomycin: A Retrospective Medical Record Review Study and an Analysis of Spontaneous Reports in the EudraVigilance Database.静脉注射磷霉素治疗期间的高钠血症：一项回顾性病历审查研究及欧洲药物警戒数据库中自发报告分析
Front Pharmacol. 2022 Mar 29;13:844122. doi: 10.3389/fphar.2022.844122. eCollection 2022.
2
Hepatocellular carcinoma surveillance, incidence, and tumor doubling times in patients cured of hepatitis C.丙型肝炎治愈患者的肝细胞癌监测、发病率和肿瘤倍增时间。
Cancer Med. 2022 May;11(9):1995-2005. doi: 10.1002/cam4.4508. Epub 2022 Mar 9.
本文引用的文献
1
Sofosbuvir-Based Regimens for Chronic Hepatitis C in a Well-Insured U.S. Population: Patient Characteristics, Treatment Adherence, Effectiveness, and Health Care Costs, 2013-2015.基于索非布韦的方案治疗美国高保险人群中的慢性丙型肝炎：患者特征、治疗依从性、疗效和医疗保健费用，2013-2015 年。
J Manag Care Spec Pharm. 2019 Feb;25(2):195-210. doi: 10.18553/jmcp.2019.25.2.195.
2
The impact of treatment of hepatitis C with DAAs on the occurrence of HCC.DAA 治疗丙型肝炎对 HCC 发生的影响。
Liver Int. 2018 Feb;38 Suppl 1:139-145. doi: 10.1111/liv.13659.
3
Direct-acting antivirals for chronic hepatitis C.用于慢性丙型肝炎的直接作用抗病毒药物。
Cochrane Database Syst Rev. 2017 Jun 6;6(6):CD012143. doi: 10.1002/14651858.CD012143.pub2.
4
Safety of new DAAs for chronic HCV infection in a real life experience: role of a surveillance network based on clinician and hospital pharmacist.新型直接抗病毒药物治疗慢性丙型肝炎病毒感染在实际临床中的安全性：基于临床医生和医院药剂师的监测网络的作用
Infect Agent Cancer. 2017 Feb 7;12:12. doi: 10.1186/s13027-017-0119-8. eCollection 2017.
5
Adverse drug reactions: definitions, diagnosis, and management.药物不良反应：定义、诊断与处理
Lancet. 2000 Oct 7;356(9237):1255-9. doi: 10.1016/S0140-6736(00)02799-9.
Zotero 插件